Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6748722 | 0.86 | MAPT (0.61) | MEN1KMT2AMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL11838628 | 0.82 | RAB9A (0.48) | MEN1KMT2AMAPTALDH1A1RAB9A | |
| SCHEMBL3457084 | 0.81 | POLB (0.61) | MEN1KMT2AALDH1A1RAB9ANPC1 | |
| SCHEMBL10522253 | 0.79 | METAP2 (0.56) | MEN1KMT2AMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL16819693 | 0.79 | KDM4E (0.54) | MEN1KMT2AMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL29643318 | 0.78 | ALDH1A1 (0.56) | MEN1KMT2AMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL14357551 | 0.78 | ALDH1A1 (0.56) | MEN1KMT2AMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL7757842 | 0.78 | KDM4E (0.59) | MEN1KMT2AMAPTALDH1A1RAB9A | |
| SCHEMBL5230905 | 0.78 | HPGD (0.56) | MEN1KMT2AMAPTRAB9ANPC1 | |
| SCHEMBL162827 | 0.78 | MAPT (0.54) | MEN1KMT2AMAPTALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106336349-B | Bromo trifluoromethoxy compound and its synthetic method | 南京优氟医药科技有限公司 | 2019-08-02 | — | — | CN | claimed |
| JP-7053489-A | — | — | None | — | — | JP | disclosed |
| US-10646850-B2 | Material for blood purification | TORAY INDUSTRIES, INC. (JP) | 2020-05-12 | — | — | US | disclosed |
| US-20190184371-A1 | MATERIAL FOR BLOOD PURIFICATION | TORAY INDUSTRIES, INC. (JP) | 2019-06-20 | — | — | US | disclosed |
| EP-3495359-A1 | FLAP MODULATORS | Janssen Pharmaceutica NV (BE) | 2019-06-12 | — | — | EP | disclosed |
| EP-3070085-B1 | FLAP MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-01-09 | — | — | EP | disclosed |
| EP-2951170-B1 | FLAP MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-10-24 | — | — | EP | disclosed |
| US-9884878-B2 | FLAP modulators | JANSSEN PHARMACEUTICA NV (BE) | 2018-02-06 | — | — | US | disclosed |
| US-9745328-B2 | Flap modulators | JANSSEN PHARMACEUTICA NV (BE) | 2017-08-29 | — | — | US | disclosed |
| EP-3070085-A1 | FLAP MODULATORS | Janssen Pharmaceutica N.V. (BE) | 2016-09-21 | — | — | EP | disclosed |
| US-20150376212-A1 | FLAP MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-12-31 | — | — | US | disclosed |
| US-20150259357-A1 | FLAP MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-09-17 | — | — | US | disclosed |
| US-9079866-B2 | Flap modulators | JANSSEN PHARMACEUTICA NV (BE) | 2015-07-14 | — | — | US | disclosed |
| US-20140221311-A1 | FLAP MODULATORS | JANSSEN PHARMACEUTICA NV (US) | 2014-08-07 | — | — | US | disclosed |
| US-20090227588-A1 | Substituted pyrazole compounds useful as soluble epoxide hyrolase inhibitors | FLECK ROMAN WOLFGANG | 2009-09-10 | — | — | US | disclosed |
| US-20090227588-A1 | Substituted pyrazole compounds useful as soluble epoxide hyrolase inhibitors | FLECK ROMAN WOLFGANG | 2009-09-10 | — | — | US | disclosed |
| JP-H0753489-A | PRODUCTION OF BIPHENYLCARBOXAMIDE | SANKYO CO LTD | 1995-02-28 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150376212-A1 | FLAP MODULATORS | FEN1, PGF, TBXA2R | MEN1 1999/4885KMT2A 3635/4885MAPT 4864/4885 |
| US-20090227588-A1 | Substituted pyrazole compounds useful as soluble epoxide hyrolase inhibitors | EPHX1, EPHX2, EPX | MEN1 4409/4885KMT2A 3792/4885MAPT 4084/4885 |
| US-20150259357-A1 | FLAP MODULATORS | PGF, FEN1, TBXA2R | MEN1 2864/4885KMT2A 3824/4885MAPT 4867/4885 |
| US-20140221311-A1 | FLAP MODULATORS | PGF, FEN1, TBXA2R | MEN1 2864/4885KMT2A 3824/4885MAPT 4867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.